CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 802 enrolled
Drug / intervention
BioMonitordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02341534
NCT02341534N/ACompleted
CompareCT.gov

BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction

Biotronik SE & Co. KG·interventional·Posted Jan 19, 2015·Updated Apr 13, 2023

In Brief

A clinical study evaluating BioMonitor for Myocardial Infarction and 2 related conditions. Completed, enrolled 802 participants across 59 sites in 14 countries.

Detailed Summary

The BIO\|GUARD-MI study investigates whether continuous arrhythmia monitoring and the consequent treatment after detected arrhythmias in patients after myocardial infarction with preserved cardiac function, but other risk factors, decreases the risk of major adverse cardiac events.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction, Myocardial Infarction, Acute, Myocardial Infarction Old
CountriesAustralia, Austria, Belgium, Czechia, Denmark, France, Germany, Hungary, Latvia, Netherlands, Poland, Slovakia, Spain, United States
CollaboratorsIHF GmbH - Institut für Herzinfarktforschung, Qmed Consulting A/S

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 19, 2015
Enrollment StartAug 7, 2015
Primary CompletionNov 3, 2021
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 11.5 years ago

Interventions

BioMonitordevice

Patients will be implanted with the BioMonitor + Home Monitoring feature